Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years60세 이상 성인에서 SARS-CoV-2 BNT162b2 백신 3차 접종 전후의 항체 역가Article Published on 2021-12-072022-09-12 Journal: JAMA [Category] SARS, 진단, [키워드] anti-S BNT162b2 booster dose IgG antibody titer individual Older the SARS-CoV-2 titer Year [DOI] 10.1001/jama.2021.19885 PMC 바로가기 [Article Type] Article
Limited and Short-Lasting Virus Neutralizing Titers Induced by Inactivated SARS-CoV-2 Vaccine비활성화된 SARS-CoV-2 백신에 의해 유도된 제한적이고 단기적인 바이러스 중화 역가Research Letter Published on 2021-12-012022-09-10 Journal: Emerging Infectious Diseases [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome CoronaVac coronavirus coronavirus disease COVID 19 Inactivated SARS-CoV-2 vaccine induced Limited Neutralizing antibodies neutralizing antibody original virus strain recipient recipients respiratory respiratory infections SARS-CoV-2 serum sample serum samples severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Support Thailand These data titer vaccination Vaccine variants variants of concern viruses [DOI] 10.3201/eid2712.211772 PMC 바로가기 [Article Type] Research Letter
Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta VariantArticle Published on 2021-11-272022-10-31 Journal: Diagnostics [Category] COVID-19, [키워드] Abbott SARS-CoV-2 IgG Affect anti-N IgG anti-RBD Anti-RBD IgG antibody antibody assay Antibody binding Antibody test Antibody titer B.1.351 Beta Beta variant binding antibody Concentration correlation COVID-19 COVID-19 case COVID-19 patients current determine Effectiveness geometric GMT IgG Lineage Live virus microneutralization Mutation neutralization neutralizing antibody Neutralizing antibody titer nucleocapsid predict Protein RBD Receptor binding domain receptor binding site required SARS-CoV-2 SARS-CoV-2 variant significantly lower Spearman spike protein RBD the SARS-CoV-2 titer Vaccine variant variants virus VoC VOCs was determined were measured wild type [DOI] 10.3390/diagnostics11122216 PMC 바로가기 [Article Type] Article
Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal StudyPreventive Medicine Published on 2021-11-252022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome Administered affecting age Analysis antibody antibody kinetics Antibody titer AstraZeneca vaccine average AZD1222 binding antibody unit blood sample BMI booster dose Breakthrough infection breakthrough infections ChAdOx1 chadox1 ncov19 vaccine ChAdOx1 vaccine chemiluminescence collected conducted coronavirus Coronavirus disease 2019 COVID vaccine COVID-19 COVID-19 vaccine Covishield dose doses Factor Factors first dose geometric globe healthcare facility Healthcare professional history IgG IgG titer immunoassay Immunoglobulin intramuscularly Kinetics linear mixed model longitudinal material Medical Science men Microparticle mixed model Nurses obese occurred Older overweight pandemic participant Person potential benefit Prospective Research Result SARS-CoV-2 SARS-COV-2 infection second dose seroreversion Seven shown tested the receptor-binding domain the spike protein the vaccine titer vaccination Vaccine vaccine dose viral particle women [DOI] 10.7759/cureus.19879 PMC 바로가기 [Article Type] Preventive Medicine
Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 VaccineArticle Published on 2021-11-222022-11-15 Journal: The Journal of Infectious Diseases [Category] SARS, 변종, 진단, [키워드] ACE2 activity acute respiratory syndrome age angiotensin-converting enzyme 2 antibodies antibody B.1.1.7 B.1.351 Beta Clover competitive binding concern coronavirus coronavirus disease COVID-19 cross-neutralization cross-reactive Day demonstrated dose dose-dependent increase Gamma IgG IgG antibodies immune response immunogenicity Immunoglobulin neutralizing antibody Neutralizing titer P.1 persistence phase 1 study Placebo prefusion prevalent reported response SARS-CoV-2 SCB-2019 sera Spike protein titer vaccination Vaccine vaccine candidate variants of concern Volunteer waned wild-type SARS-CoV-2 Wuhan-Hu-1 [DOI] 10.1093/infdis/jiab447 PMC 바로가기
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 VaccineArticle Published on 2021-11-192022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] analyzed anti-S antibody Antibody titer B.1.1.7 B.1.351 variant BNT162b2 BNT162b2 vaccine COVID-19 COVID-19 vaccine D614G decrease detectable experiments first dose hcp Healthcare professional humoral immune response induce Infection Kinetics magnitude Month mRNA vaccine multicenter neutralization neutralization activity Prevent receiving Roche anti-SARS-CoV-2-S SARS-CoV-2 SARS-CoV-2 infections serological test seropositive individual serum antibody severe COVID-19 severe symptoms T 3 the antibody response the receptor-binding domain the SARS-CoV-2 the spike protein the vaccine threshold titer vaccination Vaccination strategies was tested were measured [DOI] 10.3390/vaccines9111357 PMC 바로가기 [Article Type] Article
Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study의료 종사자의 1차 및 2차 ChAdOx1 nCoV-19 백신 접종 전후 5건의 SARS-CoV-2 항체 분석 결과 비교: 전향적 다기관 연구Multicenter Study Published on 2021-11-182022-09-12 Journal: Journal of Clinical Microbiology [Category] MERS, SARS, 진단, [키워드] Abbott acute respiratory syndrome Adverse reaction antibody Antibody titer applied assay assays AstraZeneca Blood ChAdOx1 nCoV-19 changes in Characteristics contributing to coronavirus Efficacy evaluated first dose first vaccination FIVE Genscript IgG immunoassays multicenter study neutralizing antibody participant positive rate Prospective questionnaire reduced Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 pandemic SD Biosensor second second dose second vaccination serological serum sample severity Siemens Symptoms titer vaccination Vaccine Virus neutralization [DOI] 10.1128/JCM.01788-21 PMC 바로가기 [Article Type] Multicenter Study
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 VaccinesResearch Article Published on 2021-11-102022-10-30 Journal: Microbiology Spectrum [Category] COVID-19, [키워드] age and gender antibodies antibody antibody kinetics Antibody Response average binding domain BNT162b2 BNT162b2 vaccine changes in clinically clinician Cohort COVID-19 COVID-19 pandemic defined difference dosage dose regimen elicited first dose Follow-up human cell IgG IgG antibody IgG response immune system immunization immunosuppressive drugs linear Moderna mRNA mRNA platform mRNA vaccine mRNA-1273 mRNA-1273 vaccine overcome participant peaked Pfizer/BioNTech powerful tool Prospective regimens regression modeling remained response S-protein SARS-CoV-2 SARS-CoV-2 vaccine second dose seroconverted serological Serologically seronegative participants significantly higher Spike protein the SARS-CoV-2 the vaccine titer translated vaccination Vaccine Vaccines virus spike protein was used were measured [DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article
Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2이전에 SARS-CoV-2에 감염된 의료 종사자의 BNT162b2 백신 2회 용량 요법 후 스파이크 항체 역가 평가Letter to the Editor Published on 2021-11-102022-09-12 Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, [키워드] Antibody titer of BNT162b2 past infection SARS-CoV-2 spike titer Vaccine worker [DOI] 10.1128/Spectrum.01036-21 PMC 바로가기 [Article Type] Letter to the Editor
24. Longitudinal Assessment of Immune Responses to COVID-19 Vaccines in Solid Organ Transplant RecipientsOral Abstracts Published on 2021-11-042022-10-29 Journal: Open Forum Infectious Diseases [Category] COVID-19, [키워드] 95% CI anti-N IgG anti-RBD anti-S anti-S IgG Anti-S1 antibody assessment baseline black BNT162b2 board cellular response Characteristics Clinical efficacy Cohort collected consultant controls coronavirus disease COVAX COVID COVID-19 COVID-19 vaccine Cutoff DAVID demographics detect domain dose Efficacy enrolled evaluate figure first dose greater healthy healthy control humoral IgG antibodies IgG titer longitudinal magnitude median member mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 natural infection participant Pfizer Phase 3 trials plasma positive positive response prospective cohort study Quanterix Corporation RBD receive recipient recipients reducing Research respond response Result risk SARS-CoV-2 second dose serological response significantly significantly lower Simoa Solid solid organ transplant SOT spike sub-cohort subset T-cell Response table the healthy the SARS-CoV-2 threshold time timepoint timepoints titer Transplant understanding Vaccine vaccine response were excluded were used with COVID-19 [DOI] 10.1093/ofid/ofab466.024 PMC 바로가기 [Article Type] Oral Abstracts